Eli Lilly and Company (FRA:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 830.46B |
| Revenue (ttm) | 50.64B |
| Net Income (ttm) | 15.69B |
| Shares Out | n/a |
| EPS (ttm) | 17.42 |
| PE Ratio | 52.92 |
| Forward PE | 34.08 |
| Dividend | 5.35 (0.58%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | 764 |
| Average Volume | 507 |
| Open | 917.70 |
| Previous Close | 923.90 |
| Day's Range | 913.50 - 932.30 |
| 52-Week Range | 537.40 - 967.00 |
| Beta | n/a |
| RSI | 66.07 |
| Earnings Date | Feb 6, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound
Eli Lilly is cutting prices again for those who pay cash for introductory doses of the weight-loss drug Zepbound. The lowest dose vial will cost $299 a month, that would be a saving of about $50.
Eli Lilly (LLY) Reduces Zepbound Prices on Direct Platform
Eli Lilly (LLY) Reduces Zepbound Prices on Direct Platform
Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Deal
$1,086. That's the monthly cost of Zepbound before any discounts or rebates, according to Eli Lilly. The list price for Ozempic is just over $997 per month.
Eli Lilly (LLY) Reduces Zepbound Prices Amid Rising Demand for Obesity Treatments
Eli Lilly (LLY) Reduces Zepbound Prices Amid Rising Demand for Obesity Treatments
Eli Lilly lowers starting dose costs for Zepbound on direct purchase platform
Understood. Please provide the article for which you need an SEO-friendly meta description.
Eli Lilly's price cut, Thanksgiving box office, trouble for gravestone makers and more in Morning Squawk
Here are five key things investors need to know to start the trading day.
Eli Lilly cuts Zepbound price to widen access for obesity drug
Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for weight-loss therapies...
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.
Eli Lilly (LLY) Sets Tender Offer to Acquire Adverum Biotechnologies
Eli Lilly (LLY) Sets Tender Offer to Acquire Adverum Biotechnologies
Trillion-Dollar Companies Now Go To 11; Google Is No. 3
Eli Lilly recently became the 11th stock with a trillion-dollar valuation. S&P 500 titans Nvidia and Apple lead, but Google is rising fast.
Eli Lilly: The GLP-1 Leader's Sky-High P/E Makes It A Clear Hold
Discover if Eli Lilly's (LLY) record growth in GLP-1 and diabetes drugs justifies its valuation. See if now is the right time to buy or hold.
Notable healthcare headlines for the week: Sanofi, Eli Lilly, and Novo Nordisk in focus
Get the latest healthcare stock updates, key drug price negotiations, and policy changes impacting the S&P 500.
Is Eli Lilly a Millionaire Maker?
Eli Lilly just agreed to lower the price of its blockbuster GLP-1 weight loss drug. More than half of the company's revenue comes from just two weight loss drugs.
These Are 2 of the Smartest Growth Stocks to Invest $5,000 in Today
Both of these stocks are growing by leaps and bounds. MercadoLibre boasts a cohesive ecosystem that is driving revenue and profits forward.
Noteworthy Friday Option Activity: GS, LLY, INTC
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Goldman Sachs Group Inc (Symbol: GS), where a total of 25,932 contracts have traded so far, repr...
Friday Sector Laggards: Healthcare, Consumer Products
Looking at the sectors faring worst as of midday Friday, shares of Healthcare companies are underperforming other sectors, showing a 0.1% loss. Within that group, Eli Lilly (Symbol: LLY) and HCA Healt...
S&P 500 Gains and Losses Today: Intel Soars Amid Apple Deal Rumors; Eli Lilly Stock Slides
A major U.S. chipmaker got a boost from speculation that it could win a new Big Tech customer, while a high-flying pharmaceutical stock reversed some of its recent gains.
Brianne Gardner's Past Picks: Meta Platforms, Costco & Eli Lilly
Brianne Gardner, portfolio manager & senior wealth manager at Velocity Investment Partners, Raymond James, discusses her past stock picks and how they're doing
Don't expect much from Eli Lilly stock anymore, says Len Yaffee
Market expert Len Yaffee says it would be increasingly difficult for Eli Lilly (NYSE: LLY) to push higher from current levels – at least in the near-term. LLY shares have been standout performers in 2...
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Validea Detailed Fundamental Analysis - LLY
Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our P/B Growth Investor model based on the published strategy of Par...
IHE: Pharma Powerhouse ETF Despite High Fees And Valuation
iShares U.S. Pharmaceuticals ETF offers growth and dividends from top holdings like LLY, JNJ, MRK with strong earnings and sector focus. See why IHE ETF is a buy.
Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031
Eli Lilly's valuation may suggest that its market-beating days are behind it. However, the pharmaceutical giant still has significant momentum.
Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee
Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.
Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee
Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.